Vladimir Nikolaevich Serov
Vladimir Nikolaevich Serov has a total of 228 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Davidovich Makatsariya
Sechenov University
9 shared publications - Gennady Tikhonovich Sukhikh
National Medical Research Center for Obstetrics Gynecology and Perinatology Named after Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia
9 shared publications - Igor I. Baranov
Federal State Budgetary Institution «Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology» of the Russian Ministry of Health
9 shared publications - Ivan Ivanovich Dedov
Endocrinology Research Centre
8 shared publications - Jamilya Kh. Khizroeva
Sechenov University
8 shared publications - Aleksandr I. Shchegolev
Research Center for Obstetrics, Gynecology and Perinatology
7 shared publications
Latest Publications
- 31 August 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2026, 13-21
Sepsis as a cause of maternal death
- 31 August 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2026, 13-21
Sepsis as a cause of maternal death
- 30 April 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 4_2026, 23-42
Use of bovhyaluronidase azoximer in pelvic inflammatory disease: a systematic review and meta-analysis
- 30 April 2026
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 4_2026, 23-42
Use of bovhyaluronidase azoximer in pelvic inflammatory disease: a systematic review and meta-analysis
- Open Access
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- Open Access
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- 15 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (1) , 6-27
Open AccessMenopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists
More than one million women in Russia enter menopause each year. The severe estrogen deficiency associated with this transition causes symptoms that significantly impair quality of life and contribute to an increased risk of cardiovascular and metabolic diseases. Menopausal hormone therapy (MHT) is the established standard of care for menopausal symptoms. On the initiative of several professional societies (the Russian Society of Obstetricians and Gynecologists, the Russian Society of Cardiology, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Russian Society of Gynecological Endocrinology and Menopause, the Russian Association of Gerontologists and Geriatricians, the Association of Phlebologists of Russia), a Delphi panel was convened to develop a multidisciplinary expert consensus on MHT for patients with cardiovascular and metabolic diseases. The goal was to enhance research and clinical approaches to managing menopausal women. A consensus was reached at the end of the first Delphi round. The experts agreed that initiating MHT requires a thorough assessment of individual risks, including cardiovascular health and comorbidities. MHT can offset metabolic and cardiovascular risk factors in peri- and postmenopausal women by normalizing the lipid profile, improving carbohydrate metabolism, and reducing insulin resistance. An interdisciplinary approach allows for personalized MHT, minimizes potential complications, improves the quality of life for peri- and postmenopausal women, and promotes active longevity.
- Open Access
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 108-137
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice.
- 30 June 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 6_2025, 84-93
The possibilities of using machine learning and artificial intelligence methods for morphological analysis of the placenta
- 30 June 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 6_2025, 84-93
The possibilities of using machine learning and artificial intelligence methods for morphological analysis of the placenta
- Open Access
- 10 May 2025
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 19 (2) , 250-272
Fetal systemic inflammatory response syndrome, thromboinflammation and neonatal septic shock: pathogenesis, diagnostics and treatment
The article is dedicated to outlining the pathogenic mechanisms, diagnostic criteria, and treatment of systemic inflammatory response syndrome (SIRS), thromboinflammation, and septic shock in fetuses and newborns. SIRS is a body hyperreaction to external stress involving biologically active molecules, cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL) IL-1 so that a balance between inflammation and adaptive mechanisms becomes altered. Special attention is paid to fetal inflammatory response syndrome (FIRS). Here, we describe the broad impact of FIRS targeting vital organs and systems. The challenges in diagnosing and treating septic shock in newborns are discussed, highlighting a crosstalk between inflammation and hemostasis. Despite progress in understanding the molecular mechanisms underlying FIRS and sepsis, some obstacles in developing effective therapeutic strategies remain. This underscores a need for conducting targeted research to reduce morbidity and mortality related to thromboinflammation and septic shock.
- 10 May 2025
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 19 (2) , 250-272
Open AccessFetal systemic inflammatory response syndrome, thromboinflammation and neonatal septic shock: pathogenesis, diagnostics and treatment
The article is dedicated to outlining the pathogenic mechanisms, diagnostic criteria, and treatment of systemic inflammatory response syndrome (SIRS), thromboinflammation, and septic shock in fetuses and newborns. SIRS is a body hyperreaction to external stress involving biologically active molecules, cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL) IL-1 so that a balance between inflammation and adaptive mechanisms becomes altered. Special attention is paid to fetal inflammatory response syndrome (FIRS). Here, we describe the broad impact of FIRS targeting vital organs and systems. The challenges in diagnosing and treating septic shock in newborns are discussed, highlighting a crosstalk between inflammation and hemostasis. Despite progress in understanding the molecular mechanisms underlying FIRS and sepsis, some obstacles in developing effective therapeutic strategies remain. This underscores a need for conducting targeted research to reduce morbidity and mortality related to thromboinflammation and septic shock.
- 31 March 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 3_2025, 144-158
Predictors of pregnancy rate in assisted reproductive technologies: results of the IRIS observational program in the population of Russia and Kazakhstan
- 31 March 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 3_2025, 144-158
Predictors of pregnancy rate in assisted reproductive technologies: results of the IRIS observational program in the population of Russia and Kazakhstan
- Open Access
- 26 March 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (1) , 12-24
Clinical recommendations «gestational diabetes mellitus» of the russian ministry of health. Version of the year 2024
The present article contains the newest ant the most actual version of clinical recommendations “Gestational diabetes mellitus” of the Russian Ministry of Health. This document has been confirmed for the period from 2024 until 2026 year. Gestational diabetes mellitus is widely known as onset of hyperglycaemia during pregnancy that does not responds to criteria of manifesting diabetes mellitus (DM). The time of next revision is 2026 year or earlier if new evidentiary material appear. The present version of clinical recommendation has been created due to collaboration between Russian Association of Endocrinologists and Russian Society of Obstetricians and Gynecologists. The document is finally approved by scientific and practical Council of the Russian Ministry of Health.
- 26 March 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (1) , 12-24
Open AccessClinical recommendations «gestational diabetes mellitus» of the russian ministry of health. Version of the year 2024
The present article contains the newest ant the most actual version of clinical recommendations “Gestational diabetes mellitus” of the Russian Ministry of Health. This document has been confirmed for the period from 2024 until 2026 year. Gestational diabetes mellitus is widely known as onset of hyperglycaemia during pregnancy that does not responds to criteria of manifesting diabetes mellitus (DM). The time of next revision is 2026 year or earlier if new evidentiary material appear. The present version of clinical recommendation has been created due to collaboration between Russian Association of Endocrinologists and Russian Society of Obstetricians and Gynecologists. The document is finally approved by scientific and practical Council of the Russian Ministry of Health.